Research programme: oncology kinase inhibitors - Arrien Pharmaceuticals

Drug Profile

Research programme: oncology kinase inhibitors - Arrien Pharmaceuticals

Alternative Names: ARN-1032; ARN-3015; ARN-3016; ARN-3020; ARN-3236; ARN-3261; ARN-5032; ARN-7016

Latest Information Update: 26 Nov 2015

Price : $50

At a glance

  • Originator Arrien Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Salt-inducible kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Breast cancer; Diffuse large B cell lymphoma; Lung cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 26 Nov 2015 Preclinical trials in Lung cancer in USA (unspecified route) prior November 2015
  • 26 Nov 2015 Preclinical trials in Prostate cancer in USA (unspecified route) prior November 2015
  • 26 Nov 2015 Preclinical trials in Breast cancer in USA (unspecified route) prior November 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top